SeongJin Kim, CEO of MedPacto, named keynote peaker for BioKorea 2022
May 11, 2022
Presenting efficacy of Vactosertib combination therapy in the 'Immunotherapy; Cancer Treatment's New Frontier' session on 11th.
May 11, 2022- A genome-based drug discovery and clinical-stage biotechnology company, MedPacto announced that SeongJin Kim, CEO of MedPacto, was invited to speak at 'BioKorea 2022'. As a keynote speaker, he will present that Vactosertib, a novel TGF-β Type I Receptor Kinase Inhibitor, promotes anti-tumor efficacy in combination with various cancer therapies.
In the presence of leading international academics, professionals, executives, and investors in the bio-health industry, BioKorea 2022 will be held from May 11th to 13th at COEX, Seoul.
SeongJin Kim will present the efficacy of Vactosertib in combination with various cancer treatments in the 'Immunotherapy; Cancer Treatment's New Frontier' session.
Seongjin Kim will demonstrate the preclinical antitumor efficacy of Vactosertib, a TGF-β receptor I kinase inhibitor, and its immune restoration efficacy when combined with PD-1 inhibitors.
Vactosertib is a clinical drug candidate that inhibits TGF-β signaling, a pathway that is known to inhibit the therapeutic effect of immunotherapy. By modulating the tumor microenvironment, Vactosertib improves the response of various drugs and suppresses the proliferation and metastasis of cancer cells.
MedPacto is currently conducting combination trials with Vactosertib targeting several cancers such as Pancreatic, NSCLC, Bladder, Gastric, etc.
BioKorea 2022, in its 17th year, organized Under the theme of “Beyond the Pandemic, into A Next Wave”, will exchange business trends and up-to-the-minute technologies in the bio-health industry.